Keyword Connections

•  Jason Becker

Resources

• No matching connections

Communities

• No matching connections

Publications

• Cardiac arrest during long-distance running races.
  Kim JH, Malhotra R, Chiampas G, d'Hemecourt P, Troyanos C, Cianca J, Smith RN, Wang TJ, Roberts WO, Thompson PD, Baggish AL, Race Associated Cardiac Arrest Event Registry (RACER) Study Group
  (2012) N Engl J Med 366: 130-40
• Reversible cardiomyopathy associated with sunitinib and sorafenib.
  Uraizee I, Cheng S, Moslehi J
  (2011) N Engl J Med 365: 1649-50
• Telomere dysfunction induces metabolic and mitochondrial compromise.
  Sahin E, Colla S, Liesa M, Moslehi J, Müller FL, Guo M, Cooper M, Kotton D, Fabian AJ, Walkey C, Maser RS, Tonon G, Foerster F, Xiong R, Wang YA, Shukla SA, Jaskelioff M, Martin ES, Heffernan TP, Protopopov A, Ivanova E, Mahoney JE, Kost-Alimova M, Perry SR, Bronson R, Liao R, Mulligan R, Shirihai OS, Chin L, DePinho RA
  (2011) Nature 470: 359-65
• Cardiovascular imaging in clinical practice: what does late gadolinium enhance?
  Gupta DK, Kwong RY, Pfeffer MA
  (2013) JAMA 309: 929-30
• Need for Multidisciplinary Research and Data-Driven Guidelines for the Cardiovascular Care of Patients With Cancer.
  Meijers WC, Moslehi JJ
  (2019) JAMA 322: 1775-1776
• Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.
  Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W, Mays A, Friedman DL, Ginsberg JP, Hudson MM, Neglia JP, Oeffinger KC, Ritchey AK, Villaluna D, Relling MV, Bhatia S
  (2012) J Clin Oncol 30: 1415-21
• Late cardiac effects of cancer treatment.
  Lenihan DJ, Cardinale DM
  (2012) J Clin Oncol 30: 3657-64
• Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy.
  Arad M, Moskowitz IP, Patel VV, Ahmad F, Perez-Atayde AR, Sawyer DB, Walter M, Li GH, Burgon PG, Maguire CT, Stapleton D, Schmitt JP, Guo XX, Pizard A, Kupershmidt S, Roden DM, Berul CI, Seidman CE, Seidman JG
  (2003) Circulation 107: 2850-6
• Prevalence and spectrum of thin filament mutations in an outpatient referral population with hypertrophic cardiomyopathy.
  Van Driest SL, Ellsworth EG, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ
  (2003) Circulation 108: 445-51
• Cardiology patient page. Breast cancer chemotherapy and your heart.
  Unitt C, Montazeri K, Tolaney S, Moslehi J
  (2014) Circulation 129: e680-2
• Striking In vivo phenotype of a disease-associated human SCN5A mutation producing minimal changes in vitro.
  Watanabe H, Yang T, Stroud DM, Lowe JS, Harris L, Atack TC, Wang DW, Hipkens SB, Leake B, Hall L, Kupershmidt S, Chopra N, Magnuson MA, Tanabe N, Knollmann BC, George AL, Roden DM
  (2011) Circulation 124: 1001-11
• Stem cell-derived cardiomyocytes as a tool for studying proarrhythmia: a better canary in the coal mine?
  Roden DM, Hong CC
  (2013) Circulation 127: 1641-3
• Prevalence and severity of "benign" mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy.
  Van Driest SL, Ackerman MJ, Ommen SR, Shakur R, Will ML, Nishimura RA, Tajik AJ, Gersh BJ
  (2002) Circulation 106: 3085-90
• Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy.
  Moslehi J, Minamishima YA, Shi J, Neuberg D, Charytan DM, Padera RF, Signoretti S, Liao R, Kaelin WG
  (2010) Circulation 122: 1004-16
• Heart failure research continues to reveal the flaws in nature's unintelligent design.
  Sawyer DB
  (2005) Circulation 112: 2891-3
• Cancer therapy-induced cardiomyopathy: can human induced pluripotent stem cell modelling help prevent it?
  Stack JP, Moslehi J, Sayed N, Wu JC
  (2019) Eur Heart J 40: 1764-1770
• Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy.
  Perkins MJ, Van Driest SL, Ellsworth EG, Will ML, Gersh BJ, Ommen SR, Ackerman MJ
  (2005) Eur Heart J 26: 2457-62
• Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy.
  Van Driest SL, Jaeger MA, Ommen SR, Will ML, Gersh BJ, Tajik AJ, Ackerman MJ
  (2004) J Am Coll Cardiol 44: 602-10
• Are longitudinal, natural history studies the next step in genotype-phenotype translational genomics in hypertrophic cardiomyopathy?
  Ackerman MJ, Van Driest SL, Bos M
  (2005) J Am Coll Cardiol 46: 1744-6
• Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective.
  Ackerman MJ, VanDriest SL, Ommen SR, Will ML, Nishimura RA, Tajik AJ, Gersh BJ
  (2002) J Am Coll Cardiol 39: 2042-8
• Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy.
  Van Driest SL, Vasile VC, Ommen SR, Will ML, Tajik AJ, Gersh BJ, Ackerman MJ
  (2004) J Am Coll Cardiol 44: 1903-10
• Progression of heart failure from AHA/ACC stage A to stage B or even C: can we all agree we should try to prevent this from happening?
  Lenihan DJ
  (2012) J Am Coll Cardiol 60: 2513-4
• D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice.
  Akbay EA, Moslehi J, Christensen CL, Saha S, Tchaicha JH, Ramkissoon SH, Stewart KM, Carretero J, Kikuchi E, Zhang H, Cohoon TJ, Murray S, Liu W, Uno K, Fisch S, Jones K, Gurumurthy S, Gliser C, Choe S, Keenan M, Son J, Stanley I, Losman JA, Padera R, Bronson RT, Asara JM, Abdel-Wahab O, Amrein PC, Fathi AT, Danial NN, Kimmelman AC, Kung AL, Ligon KL, Yen KE, Kaelin WG, Bardeesy N, Wong KK
  (2014) Genes Dev 28: 479-90
• Emerging paradigms in cardiomyopathies associated with cancer therapies.
  Ky B, Vejpongsa P, Yeh ET, Force T, Moslehi JJ
  (2013) Circ Res 113: 754-64
• Focal energy deprivation underlies arrhythmia susceptibility in mice with calcium-sensitized myofilaments.
  Huke S, Venkataraman R, Faggioni M, Bennuri S, Hwang HS, Baudenbacher F, Knollmann BC
  (2013) Circ Res 112: 1334-44
• Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy.
  Tyska MJ, Hayes E, Giewat M, Seidman CE, Seidman JG, Warshaw DM
  (2000) Circ Res 86: 737-44
• Familial hypertrophic cardiomyopathy: is the Frank-Starling law kaput?
  Huke S, Knollmann BC
  (2013) Circ Res 112: 1409-11
• G-protein inactivator RGS6 mediates myocardial cell apoptosis and cardiomyopathy caused by doxorubicin.
  Yang J, Maity B, Huang J, Gao Z, Stewart A, Weiss RM, Anderson ME, Fisher RA
  (2013) Cancer Res 73: 1662-7
• Expression of an LMNA-N195K variant of A-type lamins results in cardiac conduction defects and death in mice.
  Mounkes LC, Kozlov SV, Rottman JN, Stewart CL
  (2005) Hum Mol Genet 14: 2167-80
• Ablation Is Associated With Increased Nitro-Oxidative Stress During Ischemia-Reperfusion Injury: Implications for Human Ischemic Cardiomyopathy.
  Zhang B, Novitskaya T, Wheeler DG, Xu Z, Chepurko E, Huttinger R, He H, Varadharaj S, Zweier JL, Song Y, Xu M, Harrell FE, Su YR, Absi T, Kohr MJ, Ziolo MT, Roden DM, Shaffer CM, Galindo CL, Wells QS, Gumina RJ
  (2017) Circ Heart Fail 10:
• Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.
  Biolo A, Ramamurthy S, Connors LH, O'Hara CJ, Meier-Ewert HK, Soo Hoo PT, Sawyer DB, Seldin DC, Seldin DS, Sam F
  (2008) Circ Heart Fail 1: 249-57
• Research priorities in sarcomeric cardiomyopathies.
  van der Velden J, Ho CY, Tardiff JC, Olivotto I, Knollmann BC, Carrier L
  (2015) Cardiovasc Res 105: 449-56
• Modelling sarcomeric cardiomyopathies in the dish: from human heart samples to iPSC cardiomyocytes.
  Eschenhagen T, Mummery C, Knollmann BC
  (2015) Cardiovasc Res 105: 424-38
• Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations.
  Binder J, Ommen SR, Gersh BJ, Van Driest SL, Tajik AJ, Nishimura RA, Ackerman MJ
  (2006) Mayo Clin Proc 81: 459-67
• Sarcomeric genotyping in hypertrophic cardiomyopathy.
  Van Driest SL, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ
  (2005) Mayo Clin Proc 80: 463-9
• Yield of genetic testing in hypertrophic cardiomyopathy.
  Van Driest SL, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ
  (2005) Mayo Clin Proc 80: 739-44
• Essential role for mitochondrial thioredoxin reductase in hematopoiesis, heart development, and heart function.
  Conrad M, Jakupoglu C, Moreno SG, Lippl S, Banjac A, Schneider M, Beck H, Hatzopoulos AK, Just U, Sinowatz F, Schmahl W, Chien KR, Wurst W, Bornkamm GW, Brielmeier M
  (2004) Mol Cell Biol 24: 9414-23
• A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo.
  Minamishima YA, Moslehi J, Padera RF, Bronson RT, Liao R, Kaelin WG
  (2009) Mol Cell Biol 29: 5729-41
• Alterations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy.
  Hamblin M, Friedman DB, Hill S, Caprioli RM, Smith HM, Hill MF
  (2007) J Mol Cell Cardiol 42: 884-95